NCT00380224View on ClinicalTrials.gov

Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 31, 2006

Study Completion Date

September 30, 2007

Conditions
Schizophrenia
Interventions
DRUG

bifeprunox, olanzapine

Trial Locations (67)

10035

New York

10312

Staten Island

14624

Rochester

15108

Pittsburgh

19149

Philadelphia

19401

Norristown

20877

Gaithersburg

27509

Butner

27599

Chapel Hill

27707

Durham

28557

Morehead City

30060

Marietta

30308

Atlanta

30912

Augusta

32256

Jacksonville

32720

DeLand

33161

North Miami

33319

Fort Lauderdale

33426

Boynton Beach

33711

St. Petersburg

37129

Murfressboro

37212

Nashville

38018

Cordova

38105

Memphis

39232

Flowood

44109

Cleveland

58102

Fargo

60077

Joliet

60194

Hoffman Estates

60540

Naperville

60631

Chicago

63110

St Louis

63118

St Louis

63128

St Louis

69101

North Platte

70601

Lake Charles

72201

Little Rock

72211

Little Rock

73118

Oklahoma City

73139

Oklahoma City

75062

Irving

75115

DeSoto

78756

Austin

83814

Coevr d'Alene

90723

Paramount

91206

Glendale

91770

Rosemead

91942

La Mesa

91950

National City

92025

Escondido

92056

Oceanside

92108

San Diego

92123

San Diego

92126

San Diego

92363

Costa Mesa

92627

Costa Mesa

92648

Huntington Beach

92705

Santa Ana

92802

Anaheim

92804

Anaheim

92805

Anaheim

92845

Garden Grove

06050

New Britain

06320

New London

01605

Worcester

08002

Cherry Hill

08021

Clementon

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00380224 - Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia. | Biotech Hunter | Biotech Hunter